相关实验视频
Updated: Sep 13, 2025

11:10
Hyperinsulinemic-euglycemic Clamps in Conscious, Unrestrained Mice
Published on: November 16, 2011
94.8K
用于诊断内源性高胰岛素血糖低血症的exenatide:一个随机的安慰剂控制,双盲,交叉验证原则研究
Matthias Hepprich1,2,3, Christina Romberg1,3, Jonathan Mudry4
1Department of Endocrinology, Diabetes and Metabolism, University Hospital Basel, Petersgraben 4, Basel 4056, Switzerland.
European journal of endocrinology
|August 1, 2025
概括
埃克萨纳提德为内源性高胰岛素血糖低血糖 (EHH) 提供了一个更快,更简单的诊断方法. 这种GLP-1受体激动剂在临床试验中表现有前途,可能取代长时间的禁食测试.
科学领域:
- 内分泌学 在内分泌学.
- 代谢障碍 代谢障碍 代谢障碍
- 诊断工具 诊断工具
背景情况:
- 72小时禁食测试是诊断内源性超胰岛素性低血糖症 (EHH) 的标准.
- 这种测试是耗时的,侵入性的,对于患者和医疗保健系统来说是昂贵的.
- 需要更有效,更为患者友好的诊断方法来诊断EHH.
研究的目的:
- 评估GLP-1受体激动剂exenatide作为EHH的新型诊断工具.
- 为了比较exenatide与安慰剂在诊断EHH时的疗效和安全性.
- 评估exenatide的潜力,以取代传统的72小时禁食测试.
主要方法:
- 一项前性,安慰剂控制,双盲,随机交叉研究.
- 确诊EHH的14名患者和14名匹配的对照人群接受了静脉注射的exenatide或安慰剂.
- 测量包括葡萄糖,胰岛素,C-和亲胰岛素超过4小时.
主要成果:
- 在42%的EHH患者中,exenatide诱导了低血糖症,而在安慰剂患者中为0% (P = .005).
- 葡萄糖极限发生在显著更早,在较低的水平与exenatide.
- 与禁食测试相比,exenatide显著缩短了低血糖的时间 (1.38比12小时).
- 埃克西纳提德被患者耐受得很好,并且被患者更喜欢.
结论:
- 埃克塞纳提德是一种有希望的,更快,更轻松的诊断工具,用于EHH.
- 它表明它有可能成为传统禁食测试的更具成本效益的替代方案.
- 需要进行更大规模的试验来确认exenatide对EHH的诊断效用.
相关概念视频
Glucagon-like Receptor Agonists
420
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
420
Oral Hypoglycemic Agents: Glinides
263
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
263
Hypoglycemia and Glucagon
338
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
338
Dipeptidyl Peptidase 4 Inhibitors
261
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
261
Insulin: Dosing Regimen and Adverse Effects
262
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
262
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
1.4K
The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are...
Insulin and C-peptide are...
1.4K

